BioLine Rx (XTAE:BLRX) Other Net Income (Loss) : ₪0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Other Net Income (Loss)?

BioLine Rx's Other Net Income (Loss) for the three months ended in Dec. 2023 was ₪0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.00 Mil.

BioLine Rx's quarterly Other Net Income (Loss) stayed the same from Jun. 2023 (₪0.00 Mil) to Sep. 2023 (₪0.00 Mil) but then increased from Sep. 2023 (₪0.00 Mil) to Dec. 2023 (₪0.00 Mil).

BioLine Rx's annual Other Net Income (Loss) stayed the same from Dec. 2021 (₪0.00 Mil) to Dec. 2022 (₪0.00 Mil) but then increased from Dec. 2022 (₪0.00 Mil) to Dec. 2023 (₪0.00 Mil).

BioLine Rx Other Net Income (Loss) Historical Data

The historical data trend for BioLine Rx's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Other Net Income (Loss) Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

BioLine Rx Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.00 Mil.

BioLine Rx Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.